Philip Hanna, MD
Neurology · Edison, NJNPI 1306846647
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,931 of the $6,581 with a category attached, or 74.9%. 38 manufacturers reported payments, led by Insightec,inc at 27.5% of the total. Reporting peaked in 2024 at $2,389 and has fallen 55.6% since, to $1,062 in 2025.
Across 196 payments — averaging $33.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insightec,inc$2K
- Abbott$1K
- AbbVie$497
- Boston Scientific$482
- Neurocrine Biosciences, Inc.$470
- Bristol Myers Squibb$328
- plus $2K from 32 others
Across 7 payments — averaging $6194.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$24K
- H. Lundbeck A S$12K
- MDD US Operations, LLC$8K
What the payments were for
- Speaking & faculty fees$190%
- Travel & lodging$1,49623%
- Food & beverage$4,93175%
- Education$1342%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insightec,inc | 10 | $1,812 |
| Abbott | 18 | $1,228 |
| AbbVie(2 entities) | 34 | $497 |
| Boston Scientific | 7 | $482 |
| Neurocrine Biosciences, Inc. | 16 | $470 |
| Bristol Myers Squibb | 21 | $328 |
| MDD US Operations, LLC | 13 | $235 |
| Teva Pharmaceuticals USA, Inc. | 9 | $227 |
| Medtronic | 3 | $210 |
| Lilly USA, LLC | 7 | $121 |
| UCB, Inc. | 7 | $106 |
| Amneal Pharmaceuticals LLC | 6 | $91 |
| SK Life Science, Inc. | 5 | $89 |
| Argenx US, Inc. | 5 | $82 |
| Alnylam Pharmaceuticals Inc. | 4 | $74 |
| Biogen | 3 | $69 |
| Novartis | 2 | $36 |
| Merz Pharmaceuticals, LLC | 2 | $36 |
| Merck | 2 | $31 |
| AstraZeneca | 2 | $30 |
| Kyowa Kirin, Inc. | 2 | $29 |
| Adamas Pharmaceuticals, Inc. | 2 | $28 |
| Lundbeck LLC | 1 | $23 |
| SPR Therapeutics, Inc | 1 | $22 |
| Vericel Corporation | 1 | $22 |
| Pfizer | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Kestra Medical Technology Services, Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Averitas Pharma Inc. | 1 | $15 |
| Otter Pharmaceuticals, LLC | 1 | $15 |
| Genentech, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Harmony Biosciences LLC | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Grifols USA, LLC | 1 | $15 |
| Amgen | 1 | $13 |
| Aucta Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Exablate$1,416
- INFINITY$278
- Proclaim Family of SCS IPGs$266
- Neuromodulation Dspsbls and Accs$246
- INGREZZA$135
- GENERAL DBS$108
How this compares
$6,581 in reported general payments places this provider in the 65th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ApokynApomorphine Hcl | 13 | $457,162 |
| IngrezzaValbenazine Tosylate | 33 | $269,789 |
| XenazineTetrabenazine | 12 | $269,597 |
| AustedoDeutetrabenazine | 11 | $157,849 |
| NeuproRotigotine | 50 | $85,990 |
| NuplazidPimavanserin Tartrate | 14 | $68,866 |
| RytaryCarbidopa/Levodopa | 34 | $39,269 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 607 | $27,486 |
| Tetrabenazine | 13 | $21,241 |
| Entacapone | 61 | $18,914 |
| Rasagiline Mesylate | 63 | $15,321 |
| AmantadineAmantadine Hcl | 175 | $8,903 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 14 | $8,805 |
| BriviactBrivaracetam | 11 | $7,773 |
| Rivastigmine | 23 | $7,694 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $470 | $269,78933 claims |
| Lundbeck LLCXenazine | $23 | $269,59712 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $227 | $157,84911 claims |
| UCB, Inc.Neupro, Briviact | $106 | $93,76461 claims |
| Amneal Pharmaceuticals LLCRytary | $91 | $39,26934 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 521 neurology providers in New Jersey.
Other neurology in Edison
- Marina SobolEdison$69K
- Igor SobolEdison$55K
- Wei Wei MaEdison$39K
- Steven BromleyAudubon$1.5M
- Mary Ann PiconeTeaneck$1.5M
- Fiona GuptaOradell$1.1M
- Matthew DavisMiddletown$567K
- Amos KatzEatontown$558K
- Monte PellmarFreehold$429K
- Marcie RabinSummit$387K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.